Upadacitinib dose adjustment in moderate‐to‐severe atopic dermatitis: insights from a multicenter real‐world study
Flavia Manzo Margiotta(Scuola Superiore Sant'Anna), Alessandra Cartocci(University of Siena), Massimo Gola(University of Florence), Laura Lazzeri(University of Siena), Valentina Dini(University of Pisa), Leonardo Pescitelli(University of Florence), Emiliano Antiga(University of Florence), Pietro Rubegni(University of Siena), Marco Romanelli(University of Pisa), Nicola Milanesi(Ospedale del Ceppo), Carlo Mazzatenta(Azienda Usl Toscana Centro), G. Montesi(University of Florence), Manfredi Magliulo(University of Florence), Sofia Lo Conte(University of Siena), Laura Calabrese(University of Siena)
Cited by 1
Related Papers
Scanning the Immunopathogenesis of Psoriasis
|International Journal of Molecular Sciences|2018|317
Chilblain‐like lesions during COVID‐19 epidemic: a preliminary study on 63 patients
|Journal of the European Academy of Dermatology and Venereology|2020|248
Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*
|British Journal of Dermatology|2020|175
The Spectrum of Spitz Nevi
|Archives of Dermatology|2005|173
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment
|Journal of the European Academy of Dermatology and Venereology|2024|126